Written by
Additional Posts
Normal 0 false false false MicrosoftInternetExplorer4
Last month the FDA (Food and Drug Administration) voted unanimously that the benefit of Advair and Symbicort outweighed the risks of adverse effects in adults. This, following concerns about reports ...
My understanding of the debate about the bronchodilators, salmeterol (Serevent) and formoterol (Foradil) and the 2 combination drugs that contain them (Advair/Symbicort), is that the concern was raised when people taking salmeterol were found to have a higher risk of death from asthma. At the time the study findings came out, the conclusion was that this drug and anything that contained it were harmful in some way. This is why the black box warning was applied to all of these drugs.
However, subsequent studies suggested that the problem was not really the drugs themselves. Instead, the real problem seemed to be that a broncodilator alone is just not an effective treatment for asthma. Given the inflammation you reference in this post that is standard with asthma (but not necessarily with COPD), experts now recommend that people with asthma get an inhaled steroid along with the bronchodilator. This is the reason why Advair and Symbicort were developed in the first place, after all.
But for people with COPD, who do not tend to have the same degree of inflammation/immune system involvement, the need for inhaled steroids may not be as great. Hence the fact that a bronchodilator alone may be a safe and effective treatment. The fact that the FDA continued to approve these drugs for COPD is rooted in that fact, not in a lack of caring about COPDers. At least that's how I see it.
You've got it, Kathi. Well said!
I was asked about the study in the context of COPD vs. Asthma, and I figured that if one person was asking aloud, there was a good chance that many others were wondering the same thing. In researching it I learned a lot and I hope our readers did, too. You did a beautiful job of summing it all up!
Jane.